quinazolines has been researched along with pd 173074 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cody, V; Galitsky, N; Gangjee, A; Luft, JR; Pangborn, W; Queener, SF | 1 |
| Epstein, D; Haley, JD; Petti, F; Sujka-Kwok, I; Thomson, S | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
| Chuu, CP; Kuo, LK; Lin, HP | 1 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Ikemura, S; Ishioka, K; Nakayama, S; Naoki, K; Ohgino, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Yasuda, H; Yoda, S | 1 |
| Ashworth, A; Campbell, J; Herrera-Abreu, MT; Knowles, MA; Pearson, A; Shnyder, SD; Turner, NC | 1 |
| Gavine, P; Gu, Y; Liu, C; Liu, YJ; Lv, J; Ni, X; Qian, J; Qian, Z; Shen, D; Su, X; Sun, Y; Xu, Y; Yin, X; Zhan, P; Zhang, J; Zhang, T | 1 |
| Aburatani, H; Fukayama, M; Hoshino, H; Hosoya, Y; Ishikawa, S; Lefor, AK; Matsubara, D; Morishima, K; Niki, T; Saito, S; Sata, N; Ui, T; Yasuda, Y | 1 |
8 other study(ies) available for quinazolines and pd 173074
| Article | Year |
|---|---|
Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.
Topics: Crystallography, X-Ray; Folic Acid Antagonists; Models, Molecular; Molecular Structure; NADP; Pneumocystis; Pyrimidines; Quinazolines; Tetrahydrofolate Dehydrogenase | 2002 |
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung Neoplasms; Mesoderm; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Electrospray Ionization; Thiophenes; Transforming Growth Factor beta; Tumor Cells, Cultured | 2008 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Biological Availability; Caffeic Acids; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromones; Curcuma; Curcumin; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Humans; Morpholines; NF-kappa B; Phenylethyl Alcohol; Phosphoinositide-3 Kinase Inhibitors; Phytotherapy; Plant Extracts; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Signal Transduction; Somatomedins; Tyrphostins | 2012 |
Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Topics: Apoptosis; Autocrine Communication; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; RNA, Small Interfering; Signal Transduction | 2013 |
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
Topics: Animals; Cell Line, Tumor; Dasatinib; ErbB Receptors; Gefitinib; Heterografts; High-Throughput Screening Assays; Humans; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles | 2013 |
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Crizotinib; Female; Humans; Lapatinib; Male; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fibroblast Growth Factors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lapatinib; Molecular Sequence Data; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor | 2015 |